First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 8, 2012, Pages 1150-1163

  Martin, Paul J ^a   Rizzo, J Douglas ^b   Wingard, John R ^c   Ballen, Karen ^d   Curtin, Peter T ^e   Cutler, Corey ^f   Litzow, Mark R ^g   Nieto, Yago ^h   Savani, Bipin N ⁱ   Schriber, Jeffrey R ^j   Shaughnessy, Paul J ^k   Wall, Donna A ^l   Carpenter, Paul A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j Virginia G Piper Cancer Center   (United States)

^k TEXAS TRANSPLANT INSTITUTE   (United States)

^l CANCERCARE MANITOBA   (Canada)

more..

Author keywords

Acute graft versus host disease; Hematopoietic cell transplantation; Treatment

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISOLONE; PREDNISONE; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADRENAL INSUFFICIENCY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; APNEA; ARTHRALGIA; AUTOIMMUNE THROMBOCYTOPENIA; AVASCULAR NECROSIS; BACKACHE; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; CYTOPENIA; DIARRHEA; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MEGADOSE; DYSPNEA; EDEMA; FATIGUE; FEVER; FLANK PAIN; GASTRITIS; GASTROINTESTINAL TOXICITY; HEADACHE; HEALTH CARE PERSONNEL; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MEDICAL LITERATURE; MEDICAL SOCIETY; MENTAL INSTABILITY; MYOPATHY; NAUSEA; NEUROTOXICITY; OSTEOPENIA; PLASMAPHERESIS; PNEUMONIA; PRACTICE GUIDELINE; PRURITUS; RASH; REVIEW; SERUM SICKNESS; SIDE EFFECT; SURVIVAL TIME; THORAX PAIN; TREATMENT OUTCOME; URTICARIA; VOMITING; WOUND HEALING;

GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLPREDNISOLONE; PREDNISONE; TRANSPLANTATION CONDITIONING;

EID: 84862137300     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.04.005     Document Type: Review

References (51)

1. Flowers M.E., Inamoto Y., Carpenter P.A., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
2. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
3. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
4. Martin P.J., Inamoto Y., Carpenter P.A., Lee S.J., Flowers M.E. Treatment of chronic graft-versus-host disease: past, present and future. Korean J Hematol 2011, 46:153-163.
5. Martin P.J., Inamoto Y., Flowers M.E., Carpenter P.A. Secondary treatment of acute graft-versus-host disease: a critical review. Biol Blood Marrow Transplant 2012, 18:982-988.
6. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007, 109:4557-4563.
7. Van Lint M.T., Uderzo C., Locasciulli A., et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998, 92:2288-2293.
8. Mielcarek M., Storer B.E., Boeckh M., et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009, 113:2888-2894.
9. Hings I.M., Filipovich A.H., Miller W.J., et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation 1993, 56:577-580.
10. Cahn J.Y., Bordigoni P., Tiberghien P., et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995, 60:939-942.
11. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104:1559-1564.
12. Cragg L., Blazar B.R., Defor T., et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000, 6:441-447.
13. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111:2470-2475.
14. Couriel D.R., Saliba R., de Lima M., et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:1555-1562.
15. Martin P.J., Nelson B.J., Appelbaum F.R., et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996, 88:824-830.
16. MacMillan M.L., DeFor T.E., Weisdorf D.J. The best endpoint for acute GVHD treatment trials. Blood 2010, 115:5412-5417.
17. Basara N., Blau W.I., Römer E., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998, 22:61-65.
18. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
19. Pidala J., Kim J., Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:881-885.
20. MacMillan M.L., Weisdorf D.J., Davies S.M., et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:40-46.
21. Rao K., Rao A., Karlsson H., Jagani M., Veys P., Amrolia P.J. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. J Pediatr Hematol Oncol 2009, 31:456-461.
22. Messina C., Locatelli F., Lanino E., et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003, 122:118-127.
23. Perfetti P., Carlier P., Strada P., et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008, 42:609-617.
24. Khoury H., Kashyap A., Adkins D.R., et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001, 27:1059-1064.
25. Perales M.A., Ishill N., Lomazow W.A., et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 2007, 40:481-486.
26. Martínez C., Solano C., Ferrá C., et al. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. Biol Blood Marrow Transplant 2009, 15:639-642.
27. Gómez-Almaguer D., Ruiz-Argüelles G.J., del Carmen Tarín-Arzaga L., et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008, 14:10-15.
28. Schub N., Günther A., Schrauder A., et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 2011, 46:143-147.
29. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004, 104:649-654.
30. Kennedy G.A., Butler J., Western R., Morton J., Durrant S., Hill G.R. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006, 37:1143-1147.
31. Srinivasan R., Chakrabarti S., Walsh T., et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124:777-786.
32. Furlong T., Martin P., Flowers M.E., et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009, 44:739-748.
33. Roy J., McGlave P.B., Filipovich A.H., et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992, 10:77-82.
34. de Lavallade H., Mohty M., Faucher C., Furst S., El-Cheikh J., Blaise D. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica 2006, 91:1438-1440.
35. Kim J.G., Sohn S.K., Kim D.H., et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004, 73:56-61.
36. Krejci M., Doubek M., Buchler T., Brychtova Y., Vorlicek J., Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005, 84:681-685.
37. Pidala J., Kim J., Perkins J., et al. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant 2010, 45:919-924.
38. Schmidt-Hieber M., Fietz T., Knauf W., et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005, 130:568-574.
39. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000, 95:83-89.
40. Willenbacher W., Basara N., Blau I.W., Fauser A.A., Kiehl M.G. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001, 112:820-823.
41. Cuthbert R.J., Phillips G.L., Barnett M.J., et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant 1992, 10:451-455.
42. Ho V.T., Zahrieh D., Hochberg E., et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:1224-1226.
43. Shaughnessy P.J., Bachier C., Grimley M., et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:188-193.
44. Macmillan M.L., Couriel D., Weisdorf D.J., et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007, 109:2657-2662.
45. Van Lint M.T., Milone G., Leotta S., et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006, 107:4177-4181.
46. Busca A., Locatelli F., Marmont F., Ceretto C., Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007, 82:45-52.
47. Wolff D., Roessler V., Steiner B., et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005, 35:1003-1010.
48. Hoda D., Pidala J., Salgado-Vila N., et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2010, 45:1347-1351.
49. Levine J.E., Logan B., Wu J., et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant 2010, 16:1693-1699.
50. Saliba R.M., Couriel D.R., Giralt S., et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 2012, 47:125-131.
51. Martin P.J. Study design and endpoints in graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:357-372.